SCHEMBL23218487

SCHEMBL23218487

CC(C)(C)OC(=O)c1oc2ccc(Br)cc2c1CBr

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 1/20 0.48
KCNH2 Q12809 1/20 0.46
TSHR P16473 6/20 0.45
MAPT P10636 2/20 0.45
LMNA P02545 2/20 0.45
KDM4E B2RXH2 2/20 0.44
HSD17B10 Q99714 2/20 0.44
TP53 P04637 1/20 0.44
ALDH1A1 P00352 2/20 0.42
HPGD P15428 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
CASP6 P55212 1/20 0.41
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
ADORA2A P29274 1/20 0.40
CASP1 P29466 1/20 0.40
CA12 O43570 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29853065 1.00 PLK1 (0.48) PLK1KCNH2TSHRMAPTLMNA
SCHEMBL31426127 0.83 TSHR (0.50) PLK1KCNH2TSHRMAPTLMNA
SCHEMBL23218446 0.83 PLK1 (0.70) PLK1KCNH2TSHRMAPTLMNA
SCHEMBL23218607 0.83 KCNH2 (0.62) KCNH2TSHRMAPTLMNAKDM4E
SCHEMBL3508906 0.82 KDM4E (0.57) KCNH2TSHRMAPTLMNAKDM4E
SCHEMBL23218945 0.75 GPR35 (0.38) PLK1MAPTALDH1A1MEN1KMT2A
SCHEMBL29591782 0.75 GPR35 (0.38) PLK1MAPTALDH1A1MEN1KMT2A
SCHEMBL23218650 0.74 TSHR (0.42) PLK1KCNH2TSHRMAPTLMNA
SCHEMBL29852865 0.74 TSHR (0.42) PLK1KCNH2TSHRMAPTLMNA
SCHEMBL25393037 0.73 PLK1 (0.70) PLK1TSHRMAPTLMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB PLK1 4495/4885KCNH2 839/4885TSHR 1199/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB PLK1 3125/4885KCNH2 4027/4885TSHR 3148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.